CurrentCareSourcePolicy N/A

UTILIZATION MANAGEMENT MEDICAL POLICY

Defines prior authorization recommendations, clinical criteria, dosing, indications (FDA-approved and supported off-label) and approval durations for intravenous and intraventricular topotecan products for oncology indications.

Policy Summary

PayerCareSource

PolicyUTILIZATION MANAGEMENT MEDICAL POLICY

Policy CodePolicy N/A

Change TypeAnnual Revision - clarified (no criteria changes)

Effective Date

Next Review Date

Key ActionPrior authorization is recommended for medical benefit coverage of topotecan; approve only patients meeting the specific criteria and dosing and document specialist (oncologist) prescribing or consultation.

SourceLink

POLICY UPDATE CHANGES

Annual Revision indicates 'No criteria changes' for 02/05/2025 review.

12Listed covered indications (FDA and supportive)

1Approval duration commonly granted (year)

≥18Minimum patient age for most indications

Coverage Summary & Recommended Indications

Coverage stance: covered with criteria for topotecan (Hycamtin and generics). This policy defines prior authorization recommendations that map FDA-approved and NCCN-supported uses to specific authorization criteria and dosing limits for each indication, including intravenous and intraventricular administration, and documents approval durations per indication.

Dosing Limits and Approval Durations

Dosing for FDA indications

Dosing limits for approvals:

ANY of the following

Intravenous dosing: Approve up to 1.5 mg/m2 administered intravenously for up to 5 days in each 21-day cycleUp to 1.5 mg/m2 IV for up to 5 days per 21-day cycle

Policy thresholds

Age≥ 18 years for most indications

IV dosing per cycleUp to 1.5 mg/m2 IV for up to 5 days per 21-day cycle

Intraventricular dosingUp to 0.4 mg administered intraventricularly no more frequently than two times a week

Medulloblastoma dosingUp to 0.75 mg/m2 IV for up to 5 doses in each 28-day cycle

Neuroblastoma dosingUp to 1.2 mg/m2 IV for up to 5 days in each 21-day cycle

Approval duration (definition note)When approval is authorized in months, 1 month = 30 days per policy

Other Uses with Supportive Evidence (Off‑label / NCCN‑supported)

Other Uses with Supportive Evidence (Off-label / NCCN-supported)

Coverage recommended if ALL listed criteria for each condition are met:

Bone cancers (osteosarcoma, Ewing sarcoma, dedifferentiated chondrosarcoma, high-grade undifferentiated pleomorphic sarcoma, mesenchymal chondrosarcoma)

Histologies
- Osteosarcoma
- Ewing sarcoma
- Dedifferentiated chondrosarcoma
- High-grade undifferentiated pleomorphic sarcoma
- Mesenchymal chondrosarcoma
Disease status: Patient has relapsed, refractory, or metastatic disease
Line of therapy: Medication is used second-line
Combination: Medication is used in combination with cyclophosphamide
Prescriber requirement: Medication is prescribed by or in consultation with an oncologist
Dosing: Approve up to 1.5 mg/m2 IV for up to 5 days in each 21-day cycleUp to 1.5 mg/m2 IV for up to 5 days per 21-day cycle

Brain metastases from small cell cancer

Age: Patient is ≥ 18 years of age≥ 18 years
Diagnosis: Patient has small cell cancer
Single-agent use: Medication will be used as a single agent
Prescriber requirement: Medication is prescribed by or in consultation with an oncologist
Dosing: Approve up to 1.5 mg/m2 IV for up to 5 days in each 21-day cycle

Leptomeningeal and spinal metastases

Age: Patient is ≥ 18 years of age≥ 18 years
Route: Medication will be administered intraventricularly
Prescriber requirement: Medication is prescribed by or in consultation with an oncologist
Dosing: Approve up to 0.4 mg administered intraventricularly no more frequently than two times a weekUp to 0.4 mg intraventricularly no more than twice weekly

Medulloblastoma (recurrent/progressive)

Disease status: Patient has recurrent or progressive medulloblastoma
Combination: Medication will be given in combination with temozolomide
Prescriber requirement: Medication is prescribed by or in consultation with an oncologist
Dosing: Approve up to 0.75 mg/m2 IV for up to 5 times in each 28-day cycleUp to 0.75 mg/m2 IV for up to 5 doses per 28-day cycle

Merkel cell carcinoma (regional or distant metastatic disease)

Age: Patient is ≥ 18 years of age≥ 18 years
Stage: Patient has regional or distant metastatic disease
Prior immunotherapy status
- Contraindication to checkpoint immunotherapy: Patient has contraindications to checkpoint immunotherapy (Bavencio/avelumab, Keytruda/pembrolizumab, Opdivo/nivolumab)
- Progressed on checkpoint immunotherapy: Patient has progressed on checkpoint immunotherapy

Neuroblastoma

Treatment intent and risk
- High-risk primary treatment: Approve for 3 months if BOTH: patient has high-risk disease AND medication is used for primary treatment
- Intermediate-risk primary treatment: Approve for 3 months if BOTH: patient has intermediate-risk disease AND medication is used for primary treatment
- Intermediate-risk subsequent treatment: Approve for 6 months if BOTH: patient has intermediate-risk disease AND medication is used for subsequent treatment
Combination: Medication is used in combination with cyclophosphamide

Rhabdomyosarcoma (non-pleomorphic)

Age: Patient is ≥ 18 years of age≥ 18 years
Histology: Patient has non-pleomorphic rhabdomyosarcoma
Prescriber requirement: Medication is prescribed by or in consultation with an oncologist
Dosing: Approve up to 1.5 mg/m2 IV for up to 5 days in each 21-day cycleUp to 1.5 mg/m2 IV for up to 5 days per 21-day cycle

Vaginal cancer (recurrent or metastatic)

Age: Patient is ≥ 18 years of age≥ 18 years
Stage: Patient has recurrent or metastatic vaginal cancer
Prescriber requirement: Medication is prescribed by or in consultation with an oncologist
Dosing: Approve up to 1.5 mg/m2 IV for up to 5 days in each 21-day cycleUp to 1.5 mg/m2 IV for up to 5 days per 21-day cycle

Endometrial carcinoma (recurrent or metastatic)

Age: Patient is ≥ 18 years of age≥ 18 years
Single-agent use: Medication will be used as a single agent
Prescriber requirement: Medication is prescribed by or in consultation with an oncologist
Dosing: Approve up to 1.5 mg/m2 IV for up to 5 days in each 21-day cycleUp to 1.5 mg/m2 IV for up to 5 days per 21-day cycle

Multiple NCCN guideline versions (various 2024–2025 versions) are cited as evidence supporting the listed FDA and off‑label uses included in the policy.

Conditions Not Recommended for Approval

Coverage not recommended for:

Circumstances not listed in the Recommended Authorization Criteria

Provider Actions & Operational Requirements

Prior Authorization

Prior authorization required

Prior authorization is recommended for medical benefit coverage of topotecan; approval is recommended only for patients meeting the specific criteria and dosing for listed indications. All approvals provided for the duration noted per indication.

All approvals provided for the duration noted per indication.

Documentation Required

Specialist prescribing requirement

Topotecan must be prescribed by or in consultation with a physician who specializes in the condition treated (oncologist); approvals require this prescriber relationship to be documented.

Billing Rule

Dose exceptions review

Requests for doses outside the dosing documented in this policy will be considered on a case-by-case basis by a clinician (Medical Director or Pharmacist).

Approvals are provided for the duration noted per indication (for example, many indications are approved for 1 year, neuroblastoma approvals specify 3 months or 6 months depending on intent). Per policy definitions, when approval is authorized in months, 1 month = 30 days.

Applicable Codes

HCPCS / J-codes (not explicitly listed in policy text)HCPCS

No codes listed

Background & Clinical Evidence

Topotecan (Hycamtin and generics) is a topoisomerase inhibitor indicated for several gynecologic and lung cancer indications and is included in multiple NCCN guidelines for additional tumor types. The policy maps FDA‑approved uses (cervical cancer, metastatic ovarian/fallopian tube/peritoneal cancer, and small cell lung cancer) and NCCN‑supported/off‑label uses (including bone cancers, brain metastases from small cell cancer, leptomeningeal/spinal metastases, medulloblastoma, Merkel cell carcinoma, neuroblastoma, rhabdomyosarcoma, vaginal cancer, and recurrent/metastatic endometrial carcinoma) to prior authorization criteria requiring specialist prescribing and specific dosing limits for each indication.

Guideline inclusion: Multiple NCCN guideline versions (2024–2025) are cited showing recommendation of topotecan across several tumor types and settings, supporting the policy’s list of FDA and NCCN‑supported uses.

Definitions & Notes

Definitions

Approval durationWhen approval is authorized in months, 1 month = 30 days per policy.

Specialist prescribing requirementTopotecan must be prescribed by or in consultation with a physician who specializes in the condition treated (oncologist).

Dose exceptions reviewRequests for doses outside documented dosing will be considered case-by-case by a clinician (Medical Director or Pharmacist).

Revision History

2025-02-05annual_revisionLatest

Annual Revision indicates No criteria changes

2024-01-17annual_revision

Prior annual revision included clinical content changes (Merkel Cell Carcinoma updates and other modifications)

2023-01-18annual_revision

Prior annual revision included clinical content changes (no criteria changes notated for this cycle)

Policy Summary

PayerCareSource

PolicyUTILIZATION MANAGEMENT MEDICAL POLICY

Policy CodePolicy N/A

Change TypeAnnual Revision - clarified (no criteria changes)

Effective Date

Next Review Date

SourceLink

On This Page

Up to 1.5 mg/m2 IV for up to 5 days per 21-day cycle

Prescriber requirement: Medication is prescribed by or in consultation with an oncologist

Dosing: Approve up to 1.5 mg/m2 IV for up to 5 days in each 21-day cycleUp to 1.5 mg/m2 IV for up to 5 days per 21-day cycle

Prescriber requirement: Medication is prescribed by or in consultation with an oncologist

Dosing: Approve up to 1.2 mg/m2 IV for up to 5 days in each 21-day cycleUp to 1.2 mg/m2 IV for up to 5 days per 21-day cycle